TSS
AGN

Thomas Story & Son’s Allergan Inc AGN Stock Holding History

Thomas Story & Son’s Portfolio AGN Stock Details AGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-13,085
Closed -$1.62M – 63
2014
Q1 		$1.62M Hold
13,085
– – 0.88% 33
2013
Q4 		$1.45M Hold
13,085
– – 0.8% 34
2013
Q3 		$1.18M Hold
13,085
– – 0.73% 33
2013
Q2 		$1.1M Buy
+13,085
New +$1.36M 0.69% 36

Other funds holding AGN

PSCM
Pershing Square Capital Management New York $13.7B AUM 13.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
State Farm Mutual Automobile Insurance
State Farm Mutual Automobile Insurance Bloomington, Illinois $127B AUM 32.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

Thomas Story & Son's AGN Position: Q2 2014 in Review

Thomas Story & Son sold out of Allergan Inc (AGN) in Q2 2014, closing a stake of 13,085 shares — an estimated $1.62M sold.

Thomas Story & Son first reported a position in AGN in Q2 2013 and held it in 4 quarters. The position peaked at $1.62M in Q1 2014. 770 funds tracked by Wall St. Rank hold AGN as of Q2 2014.

  • Thomas Story & Son reported no remaining Allergan Inc position as of Q2 2014 after selling out during the quarter.
  • Thomas Story & Son sold 13,085 Allergan Inc shares in Q2 2014, an estimated $1.62M.
  • Thomas Story & Son first reported a position in Allergan Inc in Q2 2013 and held it in 4 quarters.
  • Thomas Story & Son's Allergan Inc position peaked at $1.62M in Q1 2014.
  • 770 funds tracked by Wall St. Rank held Allergan Inc as of Q2 2014.

Based on Thomas Story & Son's 13F filing for Q2 2014, filed 1 Aug 2014.